Shares of Cogent Biosciences surged in 2025 as enthusiasm mounted over its lead drug candidate, and four top-ranking executives appear to be taking profits.

Eli Lilly (NYSE: LLY) has been on a roll in recent years, thanks to its leadership in the weight management drug market.

Niagen Bioscience continues to see improving demand for Tru Niagen, strengthening cash generation, and a debt-free balance ...

D. Boral Capital upgraded Artelo Biosciences, Inc. (NASDAQ:ARTL) on Tuesday. The analyst upgraded from Hold to Buy and introduced a price forecast of $20. Analyst Jason Kolbert wrote, “We continue to ...

Investing.com -- Ventyx Biosciences (NASDAQ:VTYX) stock surged 5% and was halted for volatility following reports that Eli Lilly (NYSE:LLY) is in advanced talks to acquire the biotech company for more ...

It is being acquired for quite a meaty premium. The buyer is a top name in the global pharmaceuticals space. The purchasing party is global pharmaceutical company Novartis, which on Sunday divulged ...

Regencell Bioscience has surged over 14,000% in three years despite having no revenue, real assets, or meaningful business fundamentals. The company lacks any product, influential promoter, or ...

LEXARIA BIOSCIENCE ($LEXX) is expected to release its quarterly earnings data on Thursday, July 10th before market open, per Finnhub. Analysts are expecting revenue ...

Days after starting a new investigational program, it announced four appointments to its scientific advisory board. All of these professionals are experts in the affliction being targeted. Less than ...

Bill McColl has 25+ years of experience as a senior producer and writer for TV, radio, and digital media leading teams of anchors, reporters, and editors in creating news broadcasts, covering some of ...